MX2011011303A - Derivados de isoxazol. - Google Patents

Derivados de isoxazol.

Info

Publication number
MX2011011303A
MX2011011303A MX2011011303A MX2011011303A MX2011011303A MX 2011011303 A MX2011011303 A MX 2011011303A MX 2011011303 A MX2011011303 A MX 2011011303A MX 2011011303 A MX2011011303 A MX 2011011303A MX 2011011303 A MX2011011303 A MX 2011011303A
Authority
MX
Mexico
Prior art keywords
present
isoxazole derivatives
concerned
formula
active compounds
Prior art date
Application number
MX2011011303A
Other languages
English (en)
Inventor
Roland Jakob-Roetne
Andrew Thomas
Matthew C Lucas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2011011303A publication Critical patent/MX2011011303A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

La presente invención se refiere a nuevos derivados de isoxazol de la fórmula I (ver fórmula (I)) en la que X, R1, R2, R3, R4 y R5 tienen los significados aquí definidos, así como sus sales y ésteres farmacéuticamente aceptables. Los compuestos activos de la presente invención tienen afinidad y selectividad para con el receptor de GABA A a5. La presente invención se refiere además a la obtención de los compuestos activos de la fórmula I, la fabricación de composiciones farmacéuticas que los contienen y su utilización como medicamentos.
MX2011011303A 2009-04-30 2010-04-27 Derivados de isoxazol. MX2011011303A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09159150 2009-04-30
PCT/EP2010/055591 WO2010125042A1 (en) 2009-04-30 2010-04-27 Isoxazole derivatives

Publications (1)

Publication Number Publication Date
MX2011011303A true MX2011011303A (es) 2011-11-18

Family

ID=42229188

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011303A MX2011011303A (es) 2009-04-30 2010-04-27 Derivados de isoxazol.

Country Status (15)

Country Link
US (2) US8227461B2 (es)
EP (1) EP2424863B1 (es)
JP (1) JP5478714B2 (es)
KR (1) KR101438261B1 (es)
CN (1) CN102395583B (es)
AR (1) AR077534A1 (es)
AU (1) AU2010243652B2 (es)
BR (1) BRPI1016192A8 (es)
CA (1) CA2750678C (es)
ES (1) ES2431389T3 (es)
IL (1) IL214251A0 (es)
MX (1) MX2011011303A (es)
SG (1) SG175316A1 (es)
TW (1) TW201043621A (es)
WO (1) WO2010125042A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101889010B (zh) * 2007-12-04 2012-12-05 弗·哈夫曼-拉罗切有限公司 异*唑-吡啶衍生物
SG175780A1 (en) * 2009-05-05 2011-12-29 Hoffmann La Roche Isoxazole-pyridazine derivatives
RU2563167C2 (ru) * 2010-11-05 2015-09-20 Ф. Хоффманн-Ля Рош Аг Применение активных фармацевтических соединений для лечения заболеваний центральной нервной системы
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
IN2014DN11027A (es) 2012-06-26 2015-09-25 Aniona Aps
WO2014001280A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001278A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001279A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
CN104411699B (zh) 2012-06-26 2017-06-13 萨尼奥纳有限责任公司 苯基三唑衍生物及其用于调节gabaa 受体复合体的用途
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3525205A1 (de) * 1984-09-11 1986-03-20 Hoechst Ag, 6230 Frankfurt Pflanzenschuetzende mittel auf basis von 1,2,4-triazolderivaten sowie neue derivate des 1,2,4-triazols
GB9808663D0 (en) 1998-04-23 1998-06-24 Merck Sharp & Dohme Therapeutic agents
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
IT1314191B1 (it) 1999-10-18 2002-12-06 Recordati Chem Pharm Derivati isossazolcarbossamidici
BR0015420A (pt) 1999-11-12 2002-07-16 Neurogen Corp Composto, composição farmacêutica, métodos de tratamento de uma doença ou de um distúrbio associados com agonismo patogênio, para a localização de receptores gabaa, em uma amostra de tecido, de inibição da ligação de um composto de benzodiazepina em um receptor gabaa, e de alteração da atividade de transdução de sinal de receptores gabaa, agonismo inverso ou antagonismo do receptor gabaa, uso de um composto, e , composição faramcêutica embalada
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
GB0108475D0 (en) 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
PL366624A1 (en) 2001-07-05 2005-02-07 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as mch selective antagonists
DE60131967D1 (de) 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
DE60225174T2 (de) 2001-11-20 2009-02-12 Eli Lilly And Co., Indianapolis Beta-3 adrenergische agonisten
GB0128160D0 (en) 2001-11-23 2002-01-16 Merck Sharp & Dohme Novel compounds
JP2006515838A (ja) 2002-11-22 2006-06-08 スミスクライン ビーチャム コーポレーション ファルネソイドｘ受容体アゴニスト
GB0318447D0 (en) 2003-08-05 2003-09-10 Merck Sharp & Dohme Therapeutic agents
RS50603B (sr) 2004-06-01 2010-05-07 F. Hoffmann-La Roche Ag. Piridin-4-il-etinil-imidazoli i pirazoli kao antagonisti mglu5 receptora
WO2005123672A2 (en) 2004-06-14 2005-12-29 Takeda San Diego, Inc. Kinase inhibitors
BRPI0516842A (pt) 2004-10-01 2008-09-23 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por lxr alfa e/ou lxr beta agonistas e uso desses compostos
EP1812427A4 (en) 2004-10-15 2009-10-14 Scripps Research Inst FATTY ACID AMIDE HYDROLASE OXADIAZOLE KETONE INHIBITORS
US20070060589A1 (en) 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
EP1904337B1 (de) 2005-07-20 2010-10-13 Prospective Concepts AG Pneumatisch verstellbare seitenwangen für fahrzeugsitze
DE602006003777D1 (de) 2005-09-19 2009-01-02 Hoffmann La Roche Isoxazolderivate als inverse gaba a alpha5 agonisten
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
ATE526318T1 (de) 2005-12-19 2011-10-15 Glaxosmithkline Llc Farnesoid-x-rezeptor-agonisten
WO2007092751A2 (en) 2006-02-03 2007-08-16 Eli Lilly And Company Compounds and methods for modulating fx-receptors
JP2007230909A (ja) 2006-03-01 2007-09-13 Univ Of Tokyo 置換イソキサゾール誘導体
WO2007137954A1 (en) * 2006-05-31 2007-12-06 F. Hoffmann-La Roche Ag Aryl-4-ethynyl-isoxazole derivatives
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
US7943653B2 (en) * 2007-08-13 2011-05-17 Janssen Pharmaceutica N.V. Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
US7943619B2 (en) * 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
CN101889010B (zh) 2007-12-04 2012-12-05 弗·哈夫曼-拉罗切有限公司 异*唑-吡啶衍生物
EP2229383B1 (en) * 2007-12-04 2017-01-18 F. Hoffmann-La Roche AG Isoxazolo-pyrazine derivatives
SG175780A1 (en) * 2009-05-05 2011-12-29 Hoffmann La Roche Isoxazole-pyridazine derivatives
SG175318A1 (en) * 2009-05-07 2011-11-28 Hoffmann La Roche Isoxazole-pyridine derivatives as gaba modulators

Also Published As

Publication number Publication date
EP2424863A1 (en) 2012-03-07
CN102395583A (zh) 2012-03-28
SG175316A1 (en) 2011-12-29
WO2010125042A1 (en) 2010-11-04
US20100280020A1 (en) 2010-11-04
EP2424863B1 (en) 2013-09-18
JP5478714B2 (ja) 2014-04-23
BRPI1016192A2 (pt) 2016-04-19
KR101438261B1 (ko) 2014-09-05
AR077534A1 (es) 2011-09-07
AU2010243652A1 (en) 2011-09-15
ES2431389T3 (es) 2013-11-26
US8227461B2 (en) 2012-07-24
TW201043621A (en) 2010-12-16
KR20120016069A (ko) 2012-02-22
IL214251A0 (en) 2011-09-27
BRPI1016192A8 (pt) 2017-10-10
US20100280019A1 (en) 2010-11-04
CN102395583B (zh) 2015-04-01
JP2012524762A (ja) 2012-10-18
CA2750678C (en) 2014-11-04
AU2010243652B2 (en) 2013-02-07
CA2750678A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
MX2011011484A (es) Derivados de isoxazol-piridina como moduladores del acido gamma-aminobutirico.
MX2011011303A (es) Derivados de isoxazol.
MX2011007772A (es) Derivados de isoxazol/o-piridina con enlazador etilo y etenilo.
MX2011007737A (es) Derivados de hidroximetil isoxazol como moduladores de acido gamma-aminobutirico a.
MX347706B (es) Derivados de triazol y su uso para trastornos neurologicos.
TN2012000125A1 (en) Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors
TW200738596A (en) Benzamide and heteroarene derivatives
GEP201606506B (en) Quinoline amide m1 receptor positive allosteric modulators
JO2962B1 (en) Aminopronic derivatives substituted as niprilicin inhibitors
MY183312A (en) Pharmaceutical formulation
MX2013005533A (es) Derivados de acido amino-bisfenil-pentanoico sustituidos como inhibidores de nep.
MX2011011489A (es) Derivados de isoxazol-piridina.
PT2323972E (pt) Compostos de tetraciclina substituídos com c7-flúor
MY187718A (en) Pharmaceutical formulations
MX2011011273A (es) Derivados de isoxazol-pirazol.
MX2009012125A (es) Compuestos terapeuticos.
WO2010129057A8 (en) Tetracycline compounds
MX345544B (es) Derivados de triazol como ligandos para receptores de acido gamma-aminobutirico (gaba).
WO2011025982A3 (en) Tetracycline compounds
MX2011012199A (es) Derivados de benzoxazolona como inhibidores de la sintasa de aldosterona.
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
WO2010132670A3 (en) Pentacycline compounds
MX2013008531A (es) Nuevos compuestos de benzodioxol-piperazina.
TN2012000105A1 (en) Spirolactam derivatives and uses of same
MX343077B (es) Nuevo derivado de octahidrotienoquinolina, composicion farmaceutica que comprende el derivado, y uso de los mismos.

Legal Events

Date Code Title Description
FG Grant or registration